EASL Studio Podcast S4 E1: Hepatitis B elimination: How far behind are we and what do we need to change to achieve it?

EASL Studio S3 E16: Liver cancer in 2022: Wrap-up & outlook

EASL Studio Podcast S3 E16: Liver cancer in 2022: Wrap-up & outlook

EASL Policy Dialogues Episode 6: Protecting our children: Junk food & liver disease

EASL Policy Dialogues Episode 5: The lives of liver patients: Prejudice and stigma

EASL Studio S3 E15: Chronic portal vein thrombosis: Anticoagulation and interventional radiology for all patients?

EASL Studio Podcast S3 E15: Chronic portal vein thrombosis: Anticoagulation and interventional radiology for all patients?

EASL Studio S3 E14: The future of hepatology

EASL Studio Podcast S3 E14: The future of hepatology

EASL Studio S3 E13: Next-generation metrics for science beyond journal impact factor and citations: The role of social media

EASL Studio Podcast S3 E13: Next-generation metrics for science beyond journal impact factor and citations: The role of social media

EASL Policy Dialogues Episode 4: Fatty liver disease: The approaching tsunami in NCDs

EASL Studio S3 E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

EASL Studio Podcast S3 E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within

EASL Studio S3 E11: Regenerative Hepatology: From stem cells to tissue engineering

EASL Studio Podcast S3 E11: Regenerative Hepatology: From stem cells to tissue engineering

EASL Studio Podcast S3 E10: Cholestatic pruritus: Can the itch be ditched?

EASL Studio S3 E10: Cholestatic pruritus: Can the itch be ditched?

EASL Studio S3 E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all?

EASL Studio Podcast S3 E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B: Who will be the winner, if at all?